大和:歐舒丹(0973.HK)盈利勝預期 重申買入評級
大和發表研究報吿指,歐舒丹(0973.HK)淨利按年增長33%,較該行預期高,而2022財年將會是ELEMIS大大增長的一年,重申買入評級,目標價由26.3港元上調至32港元。該行將其2022-23財年的每股盈利預測上調7-11%,以反映預期更樂觀的利潤。
大和表示,管理層計劃在2022財年末在中國開設5家ELEMIS品牌銷售點,並已在上海和南京簽訂了2份租約,又將ELEMIS的業務範圍進一步擴大到目前的269家絲芙蘭門店。集團對ELEMIS未來在中國實現三位數增長表示樂觀,因為它在建立品牌知名度的同時,會繼續擴張和進入新的城市。另外,管理層計劃於今年秋季在韓國、日本和台灣推出ELEMIS,並在不久的將來在迪拜、西班牙和德國開設店鋪。
另外,管理層預計,ELEMIS的海外業務在2022財年下半年將有更大的復甦,目標是淨銷售按年增長低雙位數及運營利潤增14%。目標在2024財年實現22億歐元的淨銷售額和增加15%運營利潤,其中,預料Melvita和L’Occittane au Bresil將實現收支平衡。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.